Cargando...
Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned
In the past 3 years, we have witnessed the completion of four randomized phase III studies in neuroendocrine tumors and the approval of two new drugs, everolimus and sunitinib, for the treatment of patients with well-differentiated pancreatic neuroendocrine tumors. These studies demonstrate a shift...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
AlphaMed Press
2013
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3662843/ https://ncbi.nlm.nih.gov/pubmed/23615698 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0434 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|